Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine
- 1 November 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (21) , 5335-5346
Abstract
Purpose: To develop a synergistic combination therapy for advanced pancreatic cancer, using local phototherapy and immunotherapy, and to determine the efficacy and mechanism of the novel combination therapy using a highly metastatic pancreatic tumor model in mice.Experimental Design: Mice bearing Panc02-H7 pancreatic tumors (both subcutaneous and orthotopic) were treated with noninvasive or interventional photothermal therapy, followed by local application of an immunoadjuvant. Tumor growth and animal survival were assessed. Immune cell populations within spleen and tumors were evaluated by FACS and IHC, and cytokine levels were determined by ELISA.Results: Up to 75% of mice bearing subcutaneous tumors treated with combination therapy had complete tumor regression. Local photothermal therapy exposed/released damage-associated molecular patterns, which initiated an immunogenic tumor cell death, resulting in infiltration of antigen-presenting cells and Th1 immunity. Concomitant application of immunoadjuvant amplified Th1 immunity, especially the tumor-specific cytotoxic T lymphocyte response, with increased quantity and quality of T cells. Combination therapy also induced tumor-specific immune memory, as demonstrated by resistance to tumor rechallenge and production of memory T cells. For the treatment of orthotopic tumor, the combination therapy significantly reduced the primary tumors and metastases, and prolonged the animal survival time.Conclusions: This study indicated that combination of local phototherapy and immunotherapy induced a systemic immunity against established tumors and metastases in an aggressive, preclinical pancreatic tumor model, leading to a potential clinical method for patients with advanced pancreatic cancer. Clin Cancer Res; 24(21); 5335–46. ©2018 AACR.Keywords
All Related Versions
Funding Information
- NIH (R21 EB015509, RS20132225-106, R01 CA205348)
- NIH (R01 CA138701, R01 CA186338, and R01 CA203108)
This publication has 44 references indexed in Scilit:
- A novel epigenetic CREB‐miR‐373 axis mediates ZIP4‐induced pancreatic cancer growthEMBO Molecular Medicine, 2013
- Therapeutic Cancer Vaccines: Current Status and Moving ForwardJNCI: Journal of the National Cancer Institute, 2012
- The determinants of tumour immunogenicityNature Reviews Cancer, 2012
- Current Immunotherapeutic Approaches in Pancreatic CancerJournal of Immunology Research, 2011
- Peripheral CD4+ T‐cell differentiation regulated by networks of cytokines and transcription factorsImmunological Reviews, 2010
- Vaccine Adjuvants: Putting Innate Immunity to WorkImmunity, 2010
- Down-regulation of ZIP4 by RNA Interference Inhibits Pancreatic Cancer Growth and Increases the Survival of Nude Mice with Pancreatic Cancer XenograftsClinical Cancer Research, 2009
- Polarized immune responses differentially regulate cancer developmentImmunological Reviews, 2008
- How dying cells alert the immune system to dangerNature Reviews Immunology, 2008
- Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progressionProceedings of the National Academy of Sciences, 2007